⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGM

NTLA

Intellia Therapeutics, Inc.

Healthcare · Biotechnology

12.21USD

-0.5300 (-4.16%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.
Fiscal Year End12/2025
Last Quarter End06/2026 Q2
Current/T12M(USD)
1)

Issue Data

Last PxUSD / 12.21
P/E—
Dvd Ind Yld—
P/B2.35
P/S28.8
Curr EV/T12M EBITDA-3.3
Mkt Cap (USD)1.7B
Curr EV (USD)1.3B
2)

Per Share Data

EPS T12M-3.41
DPS—
Bk Val Per Sh5.20
Rev/Sh0.45
Cash/Sh3.12
Curr Shares Out140.1M
FCF/Sh-2.61
3)

Cash Flow Analysis

P/CF-4.9
Curr P/FCF-4.9
CF/NI0.9
Dvd P/O0.0%
Cash Gen/Cash Reqd—
Csh Dvd Cov—
CFO/Sales-582.5%
Eff Interest Rate—
4)

Growth Potential

Dil EPS 1Y Gr27.4%
Cap 1Y Gr-23.0%
BPS 1Y Gr-29.8%
R&D To Sales582.7%
Retention Rate100.0%
Rev 1Y Gr16.9%
FCF 1Y Gr-11.6%
Assets 1Y Gr-29.3%
5)

Profitability

EBITDA-0.4B
EBIT-0.4B
Operating Margin-711.7%
Pretax Margin-53.2%
Net Margin-672.2%
ROA-45.6%
ROE-6424.8%
ROC-52.9%
Asset Turnover0.07
6)

Structure

Current Ratio6.65
Quick Ratio5.61
Debt/Assets8.6%
Debt/Com Eq10.1%
Net Debt/EBITDA0.08
Tot Debt/Capital9.2%
Gross Margin72.4%
EBIT/Int Exp—

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years.